SAN DIEGO—(BUSINESS WIRE)—Nov. 26, 2012—ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will host a conference call and webcast at 8:00 a.m.
Eastern Time on Tuesday, November 27, 2012 to present the top-line
results from its pivotal Phase III trial with pimavanserin in patients
with Parkinson’s disease psychosis (PDP).
The conference call may be accessed by dialing 866-783-2140 for
participants in the U.S. or Canada and 857-350-1599 for international
callers (reference passcode 26249437). A telephone replay of the
conference call may be accessed through December 11, 2012 by dialing
888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for
international callers (reference passcode 47904115). The conference call
also will be webcast live on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until December
11, 2012.
About Pimavanserin
Pimavanserin is ACADIA’s proprietary small molecule that acts
selectively as an antagonist/inverse agonist on serotonin 5-HT2A
receptors and is in Phase III development as a potential first-in-class
treatment for Parkinson’s disease psychosis. Pimavanserin can be taken
orally as a tablet once-a-day. ACADIA discovered and holds worldwide
rights to pimavanserin.
About Parkinson’s Disease Psychosis
According to the National Parkinson’s Foundation, about one million
people in the United States and from four to six million people
worldwide suffer from Parkinson’s disease. Parkinson’s disease
psychosis, or PDP, is a debilitating disorder that develops in up to 60
percent of patients with Parkinson’s disease. Currently, there is no
FDA-approved therapy to treat PDP in the United States. PDP, commonly
consisting of visual hallucinations and delusions, substantially
contributes to the burden of Parkinson’s disease and deeply affects the
quality of life of patients. PDP is associated with increased caregiver
stress and burden, nursing home placement, and increased morbidity and
mortality. There is a large unmet medical need for new therapies that
will effectively treat PDP without compromising motor control in
patients with Parkinson’s disease.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson's disease psychosis. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. and two preclinical programs directed
at Parkinson’s disease and other neurological disorders. All of ACADIA’s
product candidates are small molecules that emanate from discoveries
made using its proprietary drug discovery platform. ACADIA maintains a
website at www.acadia-pharm.com
to which ACADIA regularly posts copies of its press releases as well as
additional information and through which interested parties can
subscribe to receive email alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the progress and timing of ACADIA’s
drug discovery and development programs, either alone or with a partner,
including clinical trials and the results of clinical trials, and the
benefits to be derived from ACADIA’s product candidates, in each case
including pimavanserin. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
the risks and uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact that
past results of clinical trials may not be indicative of future trial
results. For a discussion of these and other factors, please refer to
ACADIA’s annual report on Form 10-K for the year ended December 31, 2011
as well as ACADIA’s subsequent filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. This
caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All forward-looking statements
are qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive
Vice President,
Chief Financial Officer and Chief Business
Officer
(858) 558-2871